Mostrar el registro sencillo del ítem

Artículo

dc.creatorSantisteban, Martaes
dc.creatorPérez Solans, Belénes
dc.creatorHato, Lauraes
dc.creatorUrrizola, Amaiaes
dc.creatorMejías, Luis Danieles
dc.creatorIdoate Gastearena, Miguel Ángeles
dc.creatorInogés, Susanaes
dc.date.accessioned2022-10-25T18:12:59Z
dc.date.available2022-10-25T18:12:59Z
dc.date.issued2021
dc.identifier.citationSantisteban, M., Pérez Solans, B., Hato, L., Urrizola, A., Mejías, L.D., Idoate Gastearena, M.Á. y Inogés, S. (2021). Final results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysis. Therapeutics Advances in Medical Oncology, 13. https://doi.org/10.1177/17588359211064653.
dc.identifier.issn1758-8340es
dc.identifier.issn1758-8359es
dc.identifier.urihttps://hdl.handle.net/11441/138325
dc.description.abstractBackground: Primary breast cancer (BC) has shown a higher immune infiltration than the metastatic disease, justifying the optimal scenario for immunotherapy. Recently, neoadjuvant chemotherapy (NAC) combined with immune checkpoint inhibitors has demonstrated a gain in pathological complete responses (tpCR) in patients with BC. The aim of our study is to evaluate the safety, feasibility, and efficacy of the addition of dendritic cell vaccines (DCV) to NAC in HER2-negative BC patients. Methods: Thirty-nine patients with early BC received DCV together with NAC conforming the vaccinated group (VG) and compared with 44 patients as the control group (CG). All patients received anthracyclines and taxanes-based NAC (ddECx4→Dx4) followed by surgery ± radiotherapy ± hormonotherapy. Results: The tpCR rate was 28.9% in the VG and 9.09% in the CG (p = 0.03). Pathological CR in the triple negative (TN) BC were 50.0% versus 30.7% (p = 0.25), 16.6% versus 0% in luminal B (p = 0.15), and none among luminal A patients in VG versus CG, respectively. Impact of DCV was significantly higher in the programmed cell death ligand 1 (PD-L1) negative population (p < 0.001). PD-L1 expression was increased in patients with residual disease in the VG as compared with the CG (p < 0.01). No grade ⩾3 vaccine-related adverse events occurred. With a median follow-up of 8 years, no changes were seen in event-free survival or overall survival. Phenotypic changes post DCV in peripheral blood were observed in myeloid-derived suppressor cells (MDSC), NK, and T cells. Increase in blood cell proliferation and interferon (IFN)-γ production was detected in 69% and 74% in the VG, respectively. Humoral response was also found. Clonality changes in TCR-β repertoire were detected in 67% of the patients with a drop in diversity index after treatment. Conclusion: The combination of DCV plus NAC is safe and increases tpCR, with a significant benefit among PD-L1-negative tumors. DCV modify tumor milieu and perform cellular and humoral responses in peripheral blood with no impact in outcome.es
dc.formatapplication/pdfes
dc.format.extent14 p.es
dc.language.isoenges
dc.publisherSagees
dc.relation.ispartofTherapeutics Advances in Medical Oncology, 13.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectDendritic cell vaccineses
dc.subjectNeoadjuvant chemotherapyes
dc.subjectEarly HER2-negativees
dc.subjectBreast canceres
dc.titleFinal results regarding the addition of dendritic cell vaccines to neoadjuvant chemotherapy in early HER2-negative breast cancer patients: clinical and translational analysises
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Citología e Histología Normal y Patológicaes
dc.relation.projectIDTRA-005es
dc.relation.projectIDPI 16/01245es
dc.relation.publisherversionhttp://doi.org/10.1177/17588359211064653es
dc.identifier.doi10.1177/17588359211064653es
dc.journaltitleTherapeutics Advances in Medical Oncologyes
dc.publication.volumen13es
dc.contributor.funderMinisterio de Sanidad y Política Social. Españaes
dc.contributor.funderMinisterio de Ciencia e Innovaciónes

FicherosTamañoFormatoVerDescripción
340.pdf1.033MbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional